/ 2 items

#ENTA↓

ENTA/ 09/29/2025 · 7:55 AM

Enanta Stock Drops After Mixed Results from RSV Drug Trial

Enanta Pharmaceuticals' experimental RSV drug caused stock market disappointment after failing its main goal (reducing symptom time). However, the trial showed success in important secondary areas, like clearing the virus faster.

Featured/ ETNB/ 09/19/2025 · 8:35 AM

Pharma Giant Roche Buys 89bio for up to $3.5 Billion to Fight Fatty Liver Disease

Pharma giant Roche bought 89bio for up to $3.5B. The focus is pegozafermin, a promising drug for treating MASH (severe fatty liver disease). This deal positions Roche to transform care in metabolic diseases. Shares of 89bio surged 85% on Thursday.